Upgrade Alert for Acorda Therapeutics (ACOR)
Comtex SmarTrend(R) - Mon Apr 14, 7:11AM CDT
Acorda Therapeutics (NASDAQ:ACOR) was upgraded from Market Perform to Outperform at FBR Capital today. The stock closed yesterday at $35.19 on volume of 351,000 shares, below average daily volume of 464,000. Acorda Therapeutics Inc. is a biotechnology company that is developing therapies for spinal cord injury and related neurological conditions, including multiple sclerosis. Additionally, Acorda is developing multiple approaches to regeneration and repair of the spinal cord and brain.
Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio at AAN Annual Meeting
Business Wire - Mon Apr 14, 6:30AM CDT
--- New TECFIDERA(R) (dimethyl fumarate) Data Underscore Efficacy, Consistent with Growing Global Experience with Greater than 65,000 Patients Treated Worldwide(1) -
19.4% Return Seen to Date on SmarTrend Acorda Therapeutics Call (ACOR)
Comtex SmarTrend(R) - Fri Apr 11, 11:10AM CDT
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on February 12th, 2014 at $30.98. In approximately 2 months, Acorda Therapeutics has returned 19.43% as of today's recent price of $37.00.
Acorda Therapeutics Shares Up 22.8% Since SmarTrend's Buy Recommendation (ACOR)
Comtex SmarTrend(R) - Fri Apr 04, 9:45AM CDT
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on February 12th, 2014 at $30.98. In approximately 2 months, Acorda Therapeutics has returned 22.76% as of today's recent price of $38.03.
23.1% Return Seen to Date on SmarTrend Acorda Therapeutics Call (ACOR)
Comtex SmarTrend(R) - Fri Mar 28, 9:18AM CDT
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on February 12th, 2014 at $30.98. In approximately 1 month, Acorda Therapeutics has returned 23.14% as of today's recent price of $38.15.
Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech
M2 - Thu Mar 27, 4:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rbvwd8/global) has announced the addition of the "Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech" report to their offering. Positive sentiments for the biotech sector have prevailed in the last two to three years, and the authors expect this trend to continue for the next year too. The optimism is based on the continuity in the flow of innovative products from the biotech pipeline, implementation of strategic decisions to improve cost efficiency, strengthen therapeutic leadership, and hedge against generic threats - which all lend stability to the business model. Focus and interest in Orphan diseases remains and Alexion kept everyone guessing on the possible acquisition. BMRN, Alexion are likely candidates to be acquired in this space. In the next five years the distinction between some mature biotech companies and large global pharma may become blurred especially if there is consolidation within the sector. AMGN was the first amongst the peers to declare a dividend and this has raised the bar/expectations from others too. First mAb Biosimilar (Hospira's infliximab - Inflectra) was approved in EU and the pipeline, competition intensifies despite no firm regulatory pathway being defined in the US. This report contains the detailed discussion of the key attributes of leading biotech companies' Acorda, Alexion, Amgen, Biogen Idec, Celgene, Gilead, Regeneron and Vertex. Key Topics Covered: 1. Acorda Therapeutics - Pipeline of NDDS Drugs targeting Niche Indications 2. Alexion Pharma - Focus on Innovative Drugs for Orphan/ Ultra-rare Diseases with No Competition Visible! 3. Amgen - Late-Stage Pipeline Carries Potential to Counteract Expected Headwinds 4. Biogen Idec - Near-Term Growth Prospects Driven by Core Business New Product Launches 5. Celgene - Innovative Strategies for Long Term Gains 6. Regeneron - Label Expansion Sustains Eylea's Growth Momentum Late Stage Pipeline 7. Vertex Pharma - Focus Shift to Cystic Fibrosis and Niche Indications Companies Mentioned: - Acorada - Alexion - Amgen - Biogen Idec - Celgene - Gilead Sciences - Regeneron - Vertex Pharma For more information visit http://www.researchandmarkets.com/research/rbvwd8/global
Acorda Joins Participants from Around the World in Recognizing Purple Day(R) to Raise Epilepsy Awareness
Business Wire - Wed Mar 26, 7:05AM CDT
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today joins people with epilepsy, advocacy organizations and healthcare professionals in recognizing Purple Day(R). On March 26th people in countries around the world are invited to wear purple and host events in support of epilepsy awareness. Purple Day(R) was founded in 2008 by nine-year-old Cassidy Megan of Nova Scotia, and launched internationally in 2009. The Epilepsy Association of Nova Scotia and the Anita Kaufmann Foundation in the United States are the global partners for the Purple Day campaign(R). One in 26 Americans will develop epilepsy during their lifetime.(1)
Acorda Therapeutics Has Returned 22.7% Since SmarTrend Recommendation (ACOR)
Comtex SmarTrend(R) - Thu Mar 13, 11:11AM CDT
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on February 12th, 2014 at $30.98. In approximately 4 weeks, Acorda Therapeutics has returned 22.69% as of today's recent price of $38.01.
Financial Results, FDA Reviews, and Share Price Movements - Analyst Notes on Insys, Oxygen Biotherapeutics, Acorda, Air Methods, and AcelRx
PR Newswire - Fri Mar 07, 7:00AM CST
Today, Analysts Review released its analysts' notes regarding INSYS Therapeutics, Inc. (NASDAQ: INSY), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Air Methods Corp. (NASDAQ: AIRM), and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Uptrend Call Working As Acorda Therapeutics Stock Rises 26.2% (ACOR)
Comtex SmarTrend(R) - Thu Mar 06, 9:52AM CST
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on February 12th, 2014 at $30.98. In approximately 3 weeks, Acorda Therapeutics has returned 26.17% as of today's recent price of $39.09.
Acorda Therapeutics (ACOR) Jumps: Stock Rises 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:18AM CST
Acorda Therapeutics, Inc. (ACOR) was a big mover last session, as the company saw its shares rise by roughly 8% on the day.
Acorda Therapeutics (ACOR) Marked As A Barbarian At The Gate
at The Street - Tue Mar 04, 11:41AM CST
Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
Shares of ACOR Up 18.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Feb 27, 9:23AM CST
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on February 12th, 2014 at $30.98. In approximately 2 weeks, Acorda Therapeutics has returned 18.30% as of today's recent price of $36.65.
Acorda Therapeutics to Present at the Cowen & Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 6:00AM CST
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Ron Cohen, M.D., Acorda's President and Chief Executive Officer, and Mike Rogers, Acorda's Chief Financial Officer, will present at the Cowen & Company 34th Annual Health Care Conference on Monday, March 3 at 4:10 pm ET at the Marriott Copley Plaza Hotel in Boston.
BioLineRx appoints Dr Sandra Panem to board
M2 - Tue Feb 25, 5:59AM CST
Biopharmaceutical company BioLineRx (NASDAQ:BLRX)(TASE:BLRX), headquartered in Israel, revealed on Monday the addition of Dr Sandra Panem PhD to its board of directors.
BioLineRx Appoints Dr. Sandra Panem to Board of Directors
PR Newswire - Mon Feb 24, 6:00AM CST
BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the appointment of Sandra Panem, Ph.D., to its Board of Directors.
Acorda Up After Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 1:53PM CST
Acorda misses Q4 earnings estimates
Acorda Therapeutics to Present at Citi 2014 Global Healthcare and RBC Capital Markets Conferences in February
Business Wire - Tue Feb 18, 6:00AM CST
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that it will present at the Citi 2013 Global Healthcare and RBC Capital Markets conferences in February.
Acorda Therapeutics (ACOR) Soars: Stock Adds 10% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 7:51AM CST
Acorda Therapeutics, Inc. was a big mover last session, as its shares rose over 10% on the day.